Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sciformix to Reveal Strategic Model for Talent Acquisition at the DIA 50th Annual Meeting

Published: Thursday, May 22, 2014
Last Updated: Thursday, May 22, 2014
Bookmark and Share
New career strategy aims to address talent acquisition and retention requirements for capacity expansion.

Sciformix Corporation will unveil a new strategic model for talent acquisition and retention at the DIA 50th Annual Meeting, San Diego, California, which will take place 15th to 19th June.

The new model will demonstrate the ability to cater for the increasing demand for talent in the CRO industry, enabling capacity expansion without compromising productivity and the quality of deliverables.

The talent pool for the CRO industry is currently at a critical level, with an ever increasing demand for trained candidates, especially in highly skilled roles.

The demand-supply skew has stretched the limit of current hiring practices aimed at external sourcing of experienced talent. The problem is more acute for companies such as Sciformix, that work in areas of high science and high domain where lateral hiring isn’t the solution.

Sciformix has implemented a novel model of systematized training by developing a structured curriculum both for entry level and experienced candidates. By focusing on in-house professional development, the program will provide not only a stream of trained resources, but also make experienced resources productive on complex assignments they don’t have prior experience on.

In a presentation, to take place at DIA 50th Annual Meeting on 19th June, Dr. Samyuktha Ajay, Practice Head for Clinical Research and Post-Approval Support Services at Sciformix, will outline this new strategic initiative and share the experience and benefits of the program.

Dr. Ajay said: “According to various market research reports, the CRO industry is expected to grow to $32.7 billion by next year, to over $65.0 billion by 2021, and has created an increased demand for a rich talent pool of medical, paramedical and science graduates to supply capacity expansion. CROs and their service providers are creating new positions and promoting internal employees which is driving significant movement amongst companies and, thus, creating further resource crunch. Despite candidates being readily available, finding the right match requires the adoption of a multi-dimensional strategy. Through sharing our extensive experience of in-house training at all levels, we aim to project a program which offers a structured career path and excellent retention strategy.”

The DIA 2014 50th annual meeting is the largest multidisciplinary event that brings together the community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products and therapies to patients.

DIA will provide a platform to raise the level of discussion to facilitate innovation that will change the future of health care and it will provide coverage of the full development and life cycle management of process for health care products.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sciformix Corporation CSO Honoured in PharmaVOICE 100
Dr. Chitra Lele is recognized for pioneering work in service provision across global markets.
Friday, August 01, 2014
Sciformix Awarded Pharmaceutical KPO Entrepreneurial Company of the Year
Company has received this prestigious award from Frost & Sullivan.
Thursday, July 18, 2013
Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos